Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors

被引:0
|
作者
Yared, Jean A. [1 ]
Lee, Tsung-Ying [2 ]
Cooke, Catherine E. [2 ]
Johnson, Abree [2 ]
Summers, Amanda [2 ]
Yang, Keri [3 ]
Liu, Sizhu [3 ]
Tang, Boxiong [3 ]
Onukwugha, Eberechukwu [2 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Baltimore, MD USA
[2] Univ Maryland, Sch Pharm, Dept Practice Sci & Hlth Outcomes Res, 220 Arch St, Baltimore, MD 21201 USA
[3] Beigene USA Inc, San Mateo, CA USA
关键词
Treatment patterns; social determinants of health; social vulnerability index; chronic lymphocytic leukemia; INITIAL THERAPY; IBRUTINIB; CANCER; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; VENETOCLAX; RITUXIMAB;
D O I
10.1080/10428194.2024.2310150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study characterizes the patterns and timing of CLL treatment and, to our knowledge, is the first to identify social vulnerability factors associated with CLL treatment receipt in the Medicare population. A total of 3508 Medicare beneficiaries diagnosed with CLL from 2017 to 2019 were identified. We reported the proportion of individuals who received CLL treatment and the time until the first CLL treatment receipt after the first observed claim with a CLL diagnosis. Logistic regression and time-to-event models provided adjusted odds ratios and hazard ratios associated with baseline individual-level and county-level factors. Sixteen percent of individuals received CLL treatment, and the median follow-up time was 540 d. The median time to receipt of CLL treatment was 61 d. Older age and residence in a county ranked high in social vulnerability (as defined by minority status and language) were negatively associated with treatment receipt and time to treatment receipt.
引用
收藏
页码:598 / 608
页数:11
相关论文
共 50 条
  • [31] Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
    Samuels, Courtney
    Abbott, Diana
    Niemiec, Sierra
    Tobin, Jennifer
    Falco, Angela
    Halsema, Keri
    Kamdar, Manali
    CANCER REPORTS, 2022, 5 (05)
  • [32] Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient
    Girkar, Nishat
    Zaki, Saba
    Pawar, Sunita
    Dhande, Priti
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1650 - 1653
  • [33] Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia
    Lopedote, Paolo
    Kittai, Adam S.
    Danilov, Alexey
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 977 - 987
  • [34] Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what's best for patient quality of life?
    Korycka-Wolowiec, Anna
    Wolowiec, Dariusz
    Lawnicka, Hanna
    Robak, Tadeusz
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [35] Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries
    Chiattone, Carlos
    Gomez-Almaguer, David
    Pavlovsky, Carolina
    Tuna-Aguilar, Elena J.
    Basquiera, Ana L.
    Palmer, Luis
    de Farias, Danielle Leao Cordeiro
    da Silva Araujo, Sergio Schusterschitz
    Galvez-Cardenas, Kenny Mauricio
    Gomez Diaz, Alvaro
    Lin, Jennifer H.
    Chen, Yen-wen
    Machnicki, Gerardo
    Mahler, Michelle
    Parisi, Lori
    Barreyro, Paula
    HEMATOLOGY, 2020, 25 (01) : 366 - 371
  • [36] Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
    Huntington, Scott F.
    Manzoor, Beenish S.
    Puckett, Justin T.
    Kamal-Bahl, Sachin
    Alhasani, Hasan
    Ravelo, Arliene
    Jawaid, Dureshahwar
    Doshi, Jalpa A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (14) : 2316 - 2323
  • [37] Successful Treatment of Refractory Guillain-Barre Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia
    Tzachanis, Dimitrios
    Hamdan, Ayad
    Uhlmann, Erik J.
    Joyce, Robin M.
    ACTA HAEMATOLOGICA, 2014, 132 (02) : 240 - 243
  • [38] Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
    Celli, Bartolome R.
    Navaie, Maryam
    Xu, Zhun
    Cho-Reyes, Soojin
    Dembek, Carole
    Gilmer, Todd P.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 1019 - 1031
  • [39] The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature
    Lepretre, Stephane
    Jaeger, Uli
    Janssens, Ann
    Leblond, Veronique
    Nikitin, Eugene
    Robak, Tadeusz
    Wendtner, Clemens-Martin
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 820 - 829
  • [40] Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia
    DiSogra, Kristyn Y.
    Tran, Thuy
    Arnall, Justin R.
    Janes, Amanda
    Moore, Donald C.
    Park, Steven, I
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1265 - 1269